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Abstract: Streptomyces is a diverse group of gram-positive microorganisms characterised by a complex
developmental cycle. Streptomycetes produce a number of antibiotics and other bioactive compounds
used in the clinic. Most screening campaigns looking for new bioactive molecules from actinomycetes
have been performed empirically, e.g., without considering whether the bacteria are growing under
the best developmental conditions for secondary metabolite production. These screening campaigns
were extremely productive and discovered a number of new bioactive compounds during the
so-called “golden age of antibiotics” (until the 1980s). However, at present, there is a worrying
bottleneck in drug discovery, and new experimental approaches are needed to improve the screening
of natural actinomycetes. Streptomycetes are still the most important natural source of antibiotics
and other bioactive compounds. They harbour many cryptic secondary metabolite pathways not
expressed under classical laboratory cultures. Here, we review the new strategies that are being
explored to overcome current challenges in drug discovery. In particular, we focus on those aimed at
improving the differentiation of the antibiotic-producing mycelium stage in the laboratory.
Keywords: streptomyces; screening; antibiotics; secondary metabolism; differentiation; elicitors;
morphology; liquid cultures
1. Introduction
The Streptomyces genus includes an important group of biotechnological bacteria. They produce
two-thirds of the antibiotics of medical and agricultural interest, several antitumor agents, antifungals,
and a great number of eukaryotic cell differentiation effectors, such as apoptosis inducers and
inhibitors [1]. Drug discovery from streptomycetes fell considerably after initial screenings where
the most common compounds were discovered. Antibiotic resistance is increasing dramatically,
and new antibiotics are urgently required in the clinic. Alternative methods, such as the exploration of
chemical libraries and combinatorial chemistry, have provided limited yields. Screening from nature
has resumed through methods such as exploring new environments, looking for elicitors, accessing
the metagenome, etc.
One of the most important characteristics of Streptomyces is its complex life cycle, which is closely
related to secondary metabolite production [2] (outlined in Figure 1). In solid sporulating cultures,
development starts with spore germination and the rapid development of compartmentalised hyphae
into the medium (early substrate mycelium or MI) [3]. After that, programmed cell death (PCD)
occurs (red cellular segments in Figure 1) which triggers the differentiation of the multinucleated (MII)
antibiotic-producing hyphae (late substrate mycelium, early MII) [3,4]. Then, the mycelium starts to
grow into the air forming the aerial mycelium (late MII). At the end of the cycle, there is a second
round of PCD, and most of the remaining viable hyphae undergo a process of compartmentalisation
that culminates in the formation of unigenomic spores [5].
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substrate mycelium, MI) with 1 µm average cross-membrane spacing [6]. Some of the MI cells suffer 
a first round of programmed cell death PCD (red segments). The remaining viable segments start to 
grow as a multinucleated mycelium with sporadic septa (early MII, late substrate mycelium) [6]. The 
mycelium substrate suffers a second round of PCD (red segments) and differentiates into a mycelium 
that starts to grow into the air (the medium/agar border is indicated by a brown line) (late MII, aerial 
mycelium). Part of the aerial hyphae form spore chains (black circles). In liquid cultures, there is 
germination, MI development, PCD (in the centre of the mycelial pellets) and MII differentiation (in 
the periphery of the pellets). In most species, there is no aerial mycelium formation or sporulation, 
and hyphae form pellets and clumps [2]. Secondary metabolites (outlined as yellow circles and blue 
starts) are produced by the MII hyphae.  
Surprisingly, Streptomyces differentiation as a trigger for antibiotic production remains almost 
unexplored. The absence of a developmental model to describe differentiation in liquid cultures has 
inhibited the understanding of the relationship between macroscopic morphology (pellet and clump 
formation) and differentiation. Pellet and clump formation has been classically correlated with 
secondary metabolite production, but the relationship between both processes remains obscure. Most 
authors have affirmed that pellets and clumps are fundamental for secondary metabolite production 
(e.g., retamycin in S. olindensis [8], nikkomycins in S. tendae [9], hybrid antibiotics in S. lividans [10]), 
while some authors have affirmed that pellet and clump formation reduces antibiotic production 
(e.g., nystatin in S. noursei [11], tylosin in S. fradiae [12]). More recently, our group demonstrated that 
Figure 1. Streptomyces growth in solid cultures (upper panels) and liquid cultures (lower panels).
In solid cultures (petri plates), spores germinate developing a compartmentalised mycelium (early
substrate mycelium, MI) with 1 µm average cross-membrane spacing [6]. Some of the MI cells suffer
a first round of programmed cell death PCD (red segments). The remaining viable segments start
to grow as a multinucleated mycelium with sporadic septa (early MII, late substrate mycelium) [6].
The mycelium substrate suffers a second round of PCD (red segments) and differentiates into a
mycelium that starts to grow into the air (the medium/agar border is indicated by a brown line)
(late MII, aerial mycelium). Part of the aerial hyphae form spore chains (black circles). In liquid
cultures, there is germination, MI development, PCD (in the centre of the mycelial pellets) and MII
differentiation (in the periphery of the pellets). In most species, there is no aerial mycelium formation
or sporulation, and hyphae form pellets and clumps [2]. Secondary metabolites (outlined as yellow
circles and blue starts) are produced by the MII hyphae.
Most streptomycetes do not sporulate in liquid cultures. Therefore, it was previously assumed that
under these conditions, there was no differentiation. However, industrial antibiotic production
is mostly performed in liquid cultures (flasks and bioreactors). Currently, it is known that in
liquid cultures, differentiation is comparable to that observed in solid cultures (Figure 1). In liquid
cultures, there is a first mycelium stage (MI), PCD and the differentiation of a secondary metabolite,
producing mycelium (MII). However, in most Streptomyces strains, aerial mycelium formation and
sporulation are blocked [6] (Figure 1). S. coelicolor proteomic and transcriptomic studies have shown that
physiological differentiation in liquid and solid cultures is comparable [6,7]. MII expresses/translates
the genes/proteins involved in secondary metabolism in both solid and liquid cultures [6,7].
Surprisingly, Streptomyces differentiation as a trigger for antibiotic production remains almost
unexplored. The absence of a developmental model to describe differentiation in liquid cultures
has inhibited the understanding of the relationship between macroscopic morphology (pellet and
clump formation) and differentiation. Pellet and clump formation has been classically correlated
with secondary metabolite production, but the relationship between both processes remains obscure.
Most authors have affirmed that pellets and clumps are fundamental for secondary metabolite
production (e.g., retamycin in S. olindensis [8], nikkomycins in S. tendae [9], hybrid antibiotics in
S. lividans [10]), while some authors have affirmed that pellet and clump formation reduces antibiotic
production (e.g., nystatin in S. noursei [11], tylosin in S. fradiae [12]). More recently, our group
demonstrated that one of the key events in the activation of secondary metabolite production in
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Streptomyces liquid cultures is the differentiation of MII (e.g., actinorhodin/undecylprodigiosin
production in S. coelicolor [2,13], microbial transglutaminase production in S. mobarensis [14], apigenin
and luteolin production in S. albus [15]). The differentiation of this mycelium is conditioned by PCD
of the vegetative hyphae (MI) [2], which, in liquid cultures, depends on the growth rate of the strain
and hypha aggregation (pellet/clump formation) [2,7,14–16]. However, secondary metabolism has
additional regulations (elicitors activate specific biosynthetic pathways) [17], and most Streptomyces
strains do not display all their potential secondary metabolites under standard developmental
laboratory conditions, even if they are differentiated at the MII stage [7].
Each Streptomyces strain can harbour up to 30 secondary metabolite pathways, but only a few of
these are active in usual screening processes [18]. Activating these pathways in the lab will be crucial
in the process of screening for new secondary metabolites from actinomycetes. Here, we review the
most important strategies that are being explored to activate cryptic pathways and/or those that are
being explored to enhance secondary metabolites production.
2. Screening for New Secondary Metabolites from Streptomycetes
The search for new actinomycetes in unexplored niches or from the screening of strains that
have not been previously cultivated is useful, but usually leads to the rediscovery of already known
compounds [19]. New screening strategies are necessary to overcome the current challenges of
discovering new bioactive compounds [19]. In 2013, Arryn Craney et al. [20] summarised the new
strategies that are being used to enhance secondary metabolite production and activate cryptic
pathways, dividing them into unselective and selective methods [20]. Unselective methods are
non-specific methods that are used to screen for new activities, whereas selective methods are
biosynthetic cluster-specific methods that are used to improve the production of already known
molecules [20].
Non-specific methods were largely used during “the golden age of antibiotics”, and they are still
useful. These methods include classical strategies, such as changing media components, increasing
general precursors (metabolic engineering), inducing stress responses (with heat/ethanol/salt/acid
shock, nutrient limitations) [21], and obtaining strains that overproduce secondary metabolites by
random mutagenesis [22–24]. More novel non-specific methods include ribosomal engineering
(the alteration of ribosomal proteins to activate cryptic secondary metabolites in streptomycetes) [20,25]
and the use of small molecules as elicitors of secondary metabolism [20,26] (Table 1). Differentiation
of the antibiotic producer mycelium (MII) as a non-specific method to activate antibiotic production
remains almost unexplored. There has been no previous analysis of the frequency of Streptomyces
strains that do not produce secondary metabolites because they are not differentiated at the MII stage
in the laboratory.
Biosynthetic cluster-specific methods include self-resistance engineering (upregulation of
self-resistance genes), regulatory engineering (overexpression of activators or elimination of repressors)
and genome mining to search for new biosynthetic pathways [20] (Table 2). One of the most important
biosynthetic cluster-specific methods is heterologous expression. Heterologous expression has been
used to express Streptomyces industrial enzymes, such as laccases, in microorganisms with simpler
developmental cycles than Streptomyces, such as E. coli [27]. However, the complex biosynthetic
pathways of Streptomyces rarely can be expressed in simple expression hosts, such as E. coli or Bacillus.
Thus, other streptomycetes, such as S. lividans, S. albus, S. coelicolor or S. avermitilis, are commonly
used as expression hosts [28]. The activation of cryptic metabolites through the expression of the
Streptomyces coelicolor pleiotropic regulator, AfsQ, in other streptomycetes [29] has been successfully
achieved. Combinatorial biosynthesis, chemical modification of existing molecules, has been largely
developed over the last 20 years, in particular, progress has been made in the last few years thanks to
genome mining and synthetic biology [30–32]. Differentiation of Streptomyces MII was successfully
used to enhance the production of various products [2,13–15] through its role as a trigger for antibiotic
production (described in Section 2.3).
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2.1. Streptomyces Differentiation Strategies Based on Elicitors
In the last few years, effort has been made to elucidate the mechanism by which some small
molecules (elicitors) affect differentiation and secondary metabolite production in Streptomyces
strains. Elicitors can be defined as diffusible signals that are able to induce cryptic pathways and/or
differentiation in Streptomyces cultures [17]. Some elicitors act as signals for interspecies interaction [33].
Thus, subinhibitory concentrations of certain antibiotics produced by a given Streptomyces strain
accelerate differentiation and antibiotic production in other Streptomyces strains through “pseudo”
gamma-butyrolactone receptors [33]. Another good strategy is the use of random chemical probes
(natural or synthetic) as elicitors (reviewed in [21]).
One of the most common strategies used to activate secondary metabolism and differentiation
is mimicking the ecological environment through co-cultures of different microbes [17,34].
This methodology typically uses species that have symbiotic relationships with Streptomyces in
nature [35,36] or pathogen partners that activate the production of antimicrobial compounds [37–39].
For instance, fungal elicitors (complex mix of cell walls and filtered cultures) positively affect the
production of natamycin [40], bacterial and yeast elicitors improve valinomycin production [41],
nutrients such as glucose and xylose repress the production of actinorhodin [42,43], and small
molecules, such as GlcNAc or phosphate, can trigger differentiation and antibiotic production in
S. coelicolor through the activation of actII-ORF4/redZ genes [44].
Pimentel-Elardo et al. [45] developed an activity-independent screening method based on the
use of elicitors, to prevent the rediscovery of the most active/abundant compounds. In addition,
cheminformatics techniques are used to identify the putative biological activities of identified
compounds [45]. The use of elicitors increases the production of low-abundant compounds which
were undetected in the classical activity dependent screening. The chemical elicitor “CI-ARC” has
been identified as being responsible for triggering several cryptic biosynthetic genes [45].
2.2. Differentiation Strategies Based on Macroscopic Morphology
2.2.1. The Genetic Control of Aggregation and Macroscopic Morphology in Liquid Cultures
Large-scale antibiotic production is mostly performed in liquid cultures. It is almost unanimously
accepted that the macroscopic morphology of the mycelium (pellets and clump formation) is correlated
with the production of secondary metabolites. However, it was not until recently that the genes
controlling pellet and clump formation have been characterised. The S. coelicolor mat gene cluster [46]
and the cslA, glxA, dtpA genes [47–49] are responsible for mycelial aggregation and pellet formation.
These genes could be a great tool for controlling the morphology in industrial fermentation.
The Streptomyces life cycle in liquid cultures starts with the germination of spores. Awakening
from the dormant spore state depends on the level of AMPc in the cultures [50] and involves the
small hydrophobic protein NepA, [51]. The expression of several sigma factors involved in osmotic
and oxidative stress (SigH, SigB, SigI, SigJ) undergoes remarkable changes during germination,
indicating that germination evokes stress-like cell responses [52]. Several genes encoding proteins
involved in lipid metabolism and membrane transport are overexpressed during germination [52].
The conservation of D-alanyl-D-alanine carboxypeptidase (SCO4439) contributes to the swelling phase
of germination [53]. Cell wall hydrolases participate in germination [54]. SsgA protein marks
the germinative tube emission points [55]. Recently it was described that during germination,
spores aggregate due to extracellular glycans synthesized by the MatA, MatB [46,56] and the
CslA/GlxA/DtpA proteins [56]. These aggregates determine the macroscopic morphology (pellets and
clumps) of the culture [56] which triggers PCD and the physiological differentiation of the antibiotic
producer, mycelium MII [2].
Another issue that influence secondary metabolite production is sporulation. Several streptomycetes
are able to sporulate in liquid cultures [57] and some strains, that normally do not sporulate are also
able to sporulate in bioreactors due to the stress generated in the fermenter [13]. Sporulation stops
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metabolism, including secondary metabolite production. Consequently, in industrial fermentations
and during screening for new secondary metabolites, it is important to avoid sporulation to increase
and maintain secondary metabolism for as long as possible [13].
2.2.2. Monitoring of Streptomyces Macroscopic Morphology and Differentiation in Liquid Cultures
Pellet and clump formation led to differentiation and secondary metabolism [2]. Consequently,
new methodologies to monitor macroscopic morphology have been developed. Laser diffraction
has been used to measure pellet size [58]. Flow cytometry has been used to establish pellet size
distribution of culture populations [59,60]. Recently, a useful algorithm was developed as a plug-in for
the open-source software, ImageJ, to characterize the morphology of filamentous microorganisms in
liquid cultures [61]. Mathematical models have been performed to predict the behaviour of Streptomyces
liquid cultures based on pellet/clump morphology [62,63].
Biophysical parameters (e.g., pH, viscosity, agitation, dissolved oxygen levels and surface tension,
among others) directly affect morphology and differentiation [13,64]. These parameters must be
considered when scaling up production to industrial conditions [65]. Interestingly, a recent study
downscaled liquid cultures to the 100 µL scale in microtiter plates [66], reproducing the same range
of production and morphology as large-scale bioreactors, making screening easier and facilitating
further upscaling.
2.2.3. Macroscopic Morphology Conditions, Programmed Cell Death and Second Mycelium
Differentiation in Liquid Cultures
PCD is the key event that triggers the differentiation of the antibiotic producer, mycelium (MII),
in liquid and solid cultures [2]. However, the specific signals derived from cell death are not yet known.
The production of N-acetylglucosamine from peptidoglycan dismantling accelerates development and
antibiotic production [67,68] and might be one of the signals released during PCD.
A simple methodology based on fluorometric measures of cultures stained with SYTO9 and
propidium iodide was designed to quantify PCD in liquid cultures [69]. This method allows the
efficiency of antibiotic production to be predicted based on the level of PCD [69].
Strains showing dispersed growth take a long time to suffer PCD, and sometimes, PCD does
not occur. Modify the developmental conditions to enhance PCD and MII differentiation, leads to an
improvement in secondary metabolite production. This approach was recently applied to enhance
flavonoid production in a strain of Streptomyces albus [15] and to enhance microbial transglutaminase
production from Streptomyces mobaraensis [14]. The “PCD-MII” approach complements other
approaches well; there is no secondary metabolite production without differentiation of MII, but there
are biosynthetic pathways that in addition to MII differentiation, need specific elicitors to become
active [70].
2.3. L-Forms
An interesting alternative that would avoid the problems of mycelial growth in industry, is the use
of L-forms, which are individual cells without cell walls [71]. However, until now, the antibiotic levels
reached by Streptomyces L-forms have been quite minor compared to those reached by the regular
form. Therefore, future research should explore whether L-forms could offer an industrial alternative.
2.4. Other Strategies
A big challenge in screening for new secondary metabolites is exploring non-cultivated bacteria.
The scientific community is aware of the huge quantity of microorganisms that are not cultivated under
laboratory conditions. Next Generation Sequencing revealed the big pharmacological potential of
uncultured bacteria. Innovative culturing techniques, such as the isolation chip (iChip), are being used
successfully in combination with co-cultures to grow previously uncultured bacteria [72]. The study
of unexplored niches to look for new Actinomycetes is another strategy that enables the discovery of
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new species and compounds [73–75]. The combination of these two methods is a promising strategy
to identify new compounds.
One of the newest strategies focusses on primary metabolism and vegetative growth. Very recently,
work by Schniete et al. [76] showed how genetic redundancy within actinobacterial genomes allows
functional specialization of two pyruvate kinases in Streptomyces under different life cycle stages
and environmental conditions. Genetic redundancy within actinobacteria genomes as being a key to
understanding how the plasticity of this microorganism enhances the production of clinically useful
molecules. Furthermore, Cihak et al. [77] recently described the production of secondary metabolites
during germination in Streptomyces coelicolor. The germination stage was ignored in most secondary
metabolite screening campaigns and constitutes a potential source of bioactive compounds to be
explored [77].
Table 1. Non-specific methods and some successful examples of their enforcement. “Enhance” means
an improvement in production; “cryptic” means activation of the expression of cryptic pathways.
Methods Microorganism Product Effect Ref.
Media
manipulation S. roseosporus Daptomycin Enhance [78]
Stress Response
S. venezuelae Jadomycin B Enhance [79]
S. hygroscopicus Validamycin A Enhance [21]
S. parvulus Manumycin family Cryptic [80]
S. coelicolor Ectoine, 5-hydroxyectoine Enhance [81]
S. coelicolor Methylenomycin Enhance [82]
One Strain Many
Compounds
(OSMAC)
S. parvulus 20 cryptic compounds Cryptic [80]
Random
Mutagenesis
S. clavuligerus Clavulanic acid Enhance [83]
S. hygroscopicus Rapamycin Enhance [84]
S. coelicolor Actinorhodin, Undecylprodigiosin Enhance [22]
Ribosomal
Engineering S. coelicolor Actinorhodin Enhance [85]
Engineering
Global Regulation
S. coelicolor Actinorhodin, Prodigiosin,Calcium-Dependent Antibiotic Enhance [86]
S. griseus Streptomycin Enhance [86]
S. griseochromogenes Blasticidin S Enhance [86]
Elicitors
S. coelicolor Actinorhodin Enhance [87]
S. pristinaespiralis Desferrioxamine B/E Enhance [20]
S. peucetius Doxorubicin, Baumycin Enhance [20]
S. coelicolor Actinorhodin, Undecylprodigiosin Enhance [68]
S. lividans Prodiginine Enhance [88]
S. griseus Streptomycin Enhance [21]
S. natalensis Pimaricin Enhance [89]
29 strains Cryptic compounds Cryptic [45]
Metabolic
Engineering
S. clavuligerus FK606 Enhance [90]
S. coelicolor Actinorhodin Enhance [90]
S. rimosus Oxytetracycline Enhance [91]
Co-cultures
S. rimosus MY02 Antifungal activity Enhance [36]
S. coelicolor Actinorhodin Enhance [37]
S. fradiae 007 Phenolic polyketides Enhance [38]
Marine streptomycetes See tables in reference Cryptic [39]
Conditioning
Morphology (PCD
+ MII)
S. cattleya Tienamycin Enhance
[92]
S. cinereoruber Rodomycin Enhance
Saccharopolyspora erythraea Erithromycin Enhance
S. coelicolor Actinorhodin Enhance
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Table 2. Biosynthetic cluster specific methods and some successful examples of their enforcement.
Methods Microorganism Product Effect Ref.
Engineering Self-Resistance
S. peucetius Doxorubicin, Daunorubicin Enhance [93]
S. avermitilis Avermectin, Enhance [94]
S. coelicolor Actinorhodin Enhance [95]
Regulatory Engineering
Delete repressor AbsA2~P S. coelicolor
Actinorhodin,
Undecylprodigiosin,
Calcium-dependent antibiotic
Enhance [96]
Overexpress AverR/StrR S. avermitilis Avermectin Enhance [97]
Overexpress AverR/StrR S. griseous Streptomycin Enhance [98]
Overexpress SamR0484 S. ambofaciens Stambomicin A-D Cryptic [99]
Delete repressor cmmRII S. griseus Chromomycin Enhance [100]
Delete repressor AlpW S. ambofaciens Alpomycin Enhance [101]
Heterologous Expression
S. avermitilis Streptomycin Enhance [102]
S. coelicolor Chloramphenicol Enhance [103]
S. coelicolor Congocidine Enhance [103]
S. cyaneus CECT 3335 laccase Enhance [27]
S. lividans TK24 Mithramycin A Enhance [104]
Streptomyces sp. Neothioviridamide Cryptic [105]
Several wild-type Siamycin-I Cryptic [29]
Combinatorial Biosynthesis S. albus J1074 Novel paulomycin Cryptic [31]
See table 1 in ref. [30]
Conditioning Morphology (PCD + MII) S. albus Apigenin, Luteolin Enhance [15]
S. mobarensis Microbial transglutaminase Enhance [14]
3. Conclusions
We generally face the great challenge of fighting antibiotic resistance, which is growing much faster
than our capacity to find new antimicrobials and new strategies to face this problem. The Streptomyces
genus is still a huge source of natural bioactive compounds, but we need to form new strategies to avoid
rediscovering compounds. There is not a single methodology to trigger differentiation, activate cryptic
secondary metabolism pathways and improve the discovery of new bioactive compounds. However,
the multidisciplinary biosynthetic cluster specific and non-specific approaches discussed in this
manuscript, will be key to improving the screening for new secondary metabolites from streptomycetes.
Author Contributions: P.Y. planned the topic of the review and searched the information; A.M. and P.Y. wrote
the manuscript.
Acknowledgments: We thank the Spanish “Ministerio de Economía y Competitividad” (MINECO; BIO2015-65709-R)
for financial support.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Worrall, J.A.; Vijgenboom, E. Copper mining in streptomyces: Enzymes, natural products and development.
Nat. Prod. Rep. 2010, 27, 742–756. [CrossRef] [PubMed]
2. Manteca, A.; Alvarez, R.; Salazar, N.; Yague, P.; Sanchez, J. Mycelium differentiation and antibiotic production
in submerged cultures of Streptomyces coelicolor. Appl. Environ. Microbiol. 2008, 74, 3877–3886. [CrossRef]
[PubMed]
3. Yague, P.; Willemse, J.; Koning, R.I.; Rioseras, B.; Lopez-Garcia, M.T.; Gonzalez-Quinonez, N.;
Lopez-Iglesias, C.; Shliaha, P.V.; Rogowska-Wrzesinska, A.; Koster, A.J.; et al. Subcompartmentalization
by cross-membranes during early growth of streptomyces hyphae. Nat. Commun. 2016, 7, 12467. [CrossRef]
[PubMed]
Antibiotics 2018, 7, 41 8 of 13
4. Manteca, A.; Fernandez, M.; Sanchez, J. A death round affecting a young compartmentalized mycelium
precedes aerial mycelium dismantling in confluent surface cultures of streptomyces antibioticus. Microbiology
2005, 151, 3689–3697. [CrossRef] [PubMed]
5. Flardh, K. Growth polarity and cell division in streptomyces. Curr. Opin. Microbiol. 2003, 6, 564–571. [CrossRef]
[PubMed]
6. Manteca, A.; Jung, H.R.; Schwammle, V.; Jensen, O.N.; Sanchez, J. Quantitative proteome analysis of
Streptomyces coelicolor nonsporulating liquid cultures demonstrates a complex differentiation process
comparable to that occurring in sporulating solid cultures. J. Proteome Res. 2010, 9, 4801–4811. [CrossRef]
[PubMed]
7. Yague, P.; Rodriguez-Garcia, A.; Lopez-Garcia, M.T.; Rioseras, B.; Martin, J.F.; Sanchez, J.; Manteca, A.
Transcriptomic analysis of liquid non-sporulating Streptomyces coelicolor cultures demonstrates the existence
of a complex differentiation comparable to that occurring in solid sporulating cultures. PLoS ONE 2014,
9, e86296. [CrossRef] [PubMed]
8. Giudici, R.; Pamboukian, C.R.; Facciotti, M.C. Morphologically structured model for antitumoral retamycin
production during batch and fed-batch cultivations of streptomyces olindensis. Biotechnol. Bioeng. 2004, 86,
414–424. [CrossRef] [PubMed]
9. Vecht-Lifshitz, S.E.; Sasson, Y.; Braun, S. Nikkomycin production in pellets of streptomyces tendae.
J. Appl. Bacteriol. 1992, 72, 195–200. [CrossRef] [PubMed]
10. Sarra, M.; Casas, C.; Godia, F. Continuous production of a hybrid antibiotic by Streptomyces lividans TK21
pellets in a three-phase fluidized-bed bioreactor. Biotechnol. Bioeng. 1997, 53, 601–610. [CrossRef]
11. Jonsbu, E.; McIntyre, M.; Nielsen, J. The influence of carbon sources and morphology on nystatin production
by streptomyces noursei. J. Biotechnol. 2002, 95, 133–144. [CrossRef]
12. Park, Y.; Tamura, S.; Koike, Y.; Toriyama, M.; Okabe, M. Mycelial pellet intrastructure visualization
and viability prediction in a culture of streptomyces fradiae using confocal scanning laser microscopy.
J. Ferment. Bioeng. 1997, 84, 483–486. [CrossRef]
13. Rioseras, B.; Lopez-Garcia, M.T.; Yague, P.; Sanchez, J.; Manteca, A. Mycelium differentiation and
development of Streptomyces coelicolor in lab-scale bioreactors: Programmed cell death, differentiation,
and lysis are closely linked to undecylprodigiosin and actinorhodin production. Bioresour. Technol. 2014, 151,
191–198. [CrossRef] [PubMed]
14. Treppiccione, L.; Ottombrino, A.; Luongo, D.; Maurano, F.; Manteca, A.; Lombó, F.; Rossi, M. Development
of gluten with immunomodulatory properties using mTG-active food grade supernatants from Streptomyces
mobaraensis cultures. J. Funct. Foods 2017, 34, 390–397. [CrossRef]
15. Marin, L.; Gutierrez-Del-Rio, I.; Yague, P.; Manteca, A.; Villar, C.J.; Lombo, F. De novo biosynthesis of
apigenin, luteolin, and eriodictyol in the actinomycete Streptomyces albus and production improvement by
feeding and spore conditioning. Front. Microbiol. 2017, 8, 921. [CrossRef] [PubMed]
16. Zhang, L.; Zhang, L.; Han, X.; Du, M.; Zhang, Y.; Feng, Z.; Yi, H.; Zhang, Y. Enhancement of transglutaminase
production in Streptomyces mobaraensis as achieved by treatment with excessive MgCl2. Appl. Microbiol. Biotechnol.
2012, 93, 2335–2343. [CrossRef] [PubMed]
17. Onaka, H. Novel antibiotic screening methods to awaken silent or cryptic secondary metabolic pathways in
actinomycetes. J. Antibiot. 2017, 70, 865–870. [CrossRef] [PubMed]
18. Genilloud, O. The re-emerging role of microbial natural products in antibiotic discovery. Antonie Van Leeuwenhoek
2014, 106, 173–188. [CrossRef] [PubMed]
19. Genilloud, O. Actinomycetes: Still a source of novel antibiotics. Nat. Prod. Rep. 2017, 34, 1203–1232.
[CrossRef] [PubMed]
20. Craney, A.; Ahmed, S.; Nodwell, J. Towards a new science of secondary metabolism. J. Antibiot. 2013, 66,
387–400. [CrossRef] [PubMed]
21. Yoon, V.; Nodwell, J.R. Activating secondary metabolism with stress and chemicals. J. Ind. Microbiol. Biotechnol.
2014, 41, 415–424. [CrossRef] [PubMed]
22. Xu, Z.; Wang, Y.; Chater, K.F.; Ou, H.Y.; Xu, H.H.; Deng, Z.; Tao, M. Large-scale transposition
mutagenesis of Streptomyces coelicolor identifies hundreds of genes influencing antibiotic biosynthesis.
Appl. Environ. Microbiol. 2017, 83, e02889-16. [CrossRef] [PubMed]
Antibiotics 2018, 7, 41 9 of 13
23. Khaliq, S.; Akhtar, K.; Afzal Ghauri, M.; Iqbal, R.; Mukhtar Khalid, A.; Muddassar, M. Change in colony
morphology and kinetics of tylosin production after UV and gamma irradiation mutagenesis of streptomyces
fradiae NRRL-2702. Microbiol. Res. 2009, 164, 469–477. [CrossRef] [PubMed]
24. Korbekandi, H.; Darkhal, P.; Hojati, Z.; Abedi, D.; Hamedi, J.; Pourhosein, M. Overproduction of clavulanic
acid by UV mutagenesis of Streptomyces clavuligerus. Iran. J. Pharm. Res. 2010, 9, 177–181. [CrossRef]
[PubMed]
25. Hosaka, T.; Ohnishi-Kameyama, M.; Muramatsu, H.; Murakami, K.; Tsurumi, Y.; Kodani, S.; Yoshida, M.;
Fujie, A.; Ochi, K. Antibacterial discovery in actinomycetes strains with mutations in RNA polymerase or
ribosomal protein S12. Nat. Biotechnol. 2009, 27, 462–464. [CrossRef] [PubMed]
26. Ahmed, S.; Craney, A.; Pimentel-Elardo, S.M.; Nodwell, J.R. A synthetic, speciesspecific activator of
secondary metabolism and sporulation in Streptomyces coelicolor. Chembiochem 2013, 14, 83–91. [CrossRef]
[PubMed]
27. Ece, S.; Lambertz, C.; Fischer, R.; Commandeur, U. Heterologous expression of a Streptomyces cyaneus laccase
for biomass modification applications. AMB Express 2017, 7, 86. [CrossRef] [PubMed]
28. Baltz, R.H. Streptomyces and saccharopolyspora hosts for heterologous expression of secondary metabolite
gene clusters. J. Ind. Microbiol. Biotechnol. 2010, 37, 759–772. [CrossRef] [PubMed]
29. Daniel-Ivad, M.; Hameed, N.; Tan, S.; Dhanjal, R.; Socko, D.; Pak, P.; Gverzdys, T.; Elliot, M.A.; Nodwell, J.R.
An engineered allele of afsQ1 facilitates the discovery and investigation of cryptic natural products.
ACS Chem. Biol. 2017, 12, 628–634. [CrossRef] [PubMed]
30. Olano, C.; Mendez, C.; Salas, J.A. Post-PKS tailoring steps in natural product-producing actinomycetes from
the perspective of combinatorial biosynthesis. Nat. Prod. Rep. 2010, 27, 571–616. [CrossRef] [PubMed]
31. González, A.; Rodríguez, M.; Braña, A.F.; Méndez, C.; Salas, J.A.; Olano, C. New insights into paulomycin
biosynthesis pathway in Streptomyces albus j1074 and generation of novel derivatives by combinatorial
biosynthesis. Microb. Cell Fact. 2016, 15. [CrossRef] [PubMed]
32. Baltz, R.H. Synthetic biology, genome mining, and combinatorial biosynthesis of NRPS-derived antibiotics:
A perspective. J. Ind. Microbiol. Biotechnol. 2017. [CrossRef] [PubMed]
33. Wang, W.; Ji, J.; Li, X.; Wang, J.; Li, S.; Pan, G.; Fan, K.; Yang, K. Angucyclines as signals modulate the
behaviors of Streptomyces coelicolor. Proc. Natl. Acad. Sci. USA 2014, 111, 5688–5693. [CrossRef] [PubMed]
34. Marmann, A.; Aly, A.H.; Lin, W.; Wang, B.; Proksch, P. Co-cultivation—A powerful emerging tool for
enhancing the chemical diversity of microorganisms. Mar. Drugs 2014, 12, 1043–1065. [CrossRef] [PubMed]
35. Piel, J. Metabolites from symbiotic bacteria. Nat. Prod. Rep. 2004, 21, 519–538. [CrossRef] [PubMed]
36. Yu, J.; Liu, Q.; Chen, C.; Qi, X. Antifungal activity change of streptomyces rimosus MY02 mediated by
confront culture with other microorganism. J. Basic Microbiol. 2017, 57, 276–282. [CrossRef] [PubMed]
37. Perez, J.; Munoz-Dorado, J.; Brana, A.F.; Shimkets, L.J.; Sevillano, L.; Santamaria, R.I. Myxococcus
Xanthus induces actinorhodin overproduction and aerial mycelium formation by Streptomyces coelicolor.
Microb. Biotechnol. 2011, 4, 175–183. [CrossRef] [PubMed]
38. Wang, Y.; Wang, L.; Zhuang, Y.; Kong, F.; Zhang, C.; Zhu, W. Phenolic polyketides from the co-cultivation
of marine-derived Penicillium sp. Wc-29-5 and Streptomyces fradiae 007. Mar. Drugs 2014, 12, 2079–2088.
[CrossRef] [PubMed]
39. Sung, A.A.; Gromek, S.M.; Balunas, M.J. Upregulation and identification of antibiotic activity of a
marine-derived Streptomyces sp. Via co-cultures with human pathogens. Mar. Drugs 2017, 15, 250. [CrossRef]
[PubMed]
40. Wang, D.; Yuan, J.; Gu, S.; Shi, Q. Influence of fungal elicitors on biosynthesis of natamycin by streptomyces
natalensis HW-2. Appl. Microbiol. Biotechnol. 2013, 97, 5527–5534. [CrossRef] [PubMed]
41. Sharma, R.; Jamwal, V.; Singh, V.P.; Wazir, P.; Awasthi, P.; Singh, D.; Vishwakarma, R.A.; Gandhi, S.G.;
Chaubey, A. Revelation and cloning of valinomycin synthetase genes in streptomyces lavendulae acr-da1
and their expression analysis under different fermentation and elicitation conditions. J. Biotechnol. 2017, 253,
40–47. [CrossRef] [PubMed]
42. Gubbens, J.; Janus, M.M.; Florea, B.I.; Overkleeft, H.S.; van Wezel, G.P. Identification of glucose
kinase-dependent and -independent pathways for carbon control of primary metabolism, development and
antibiotic production in Streptomyces coelicolor by quantitative proteomics. Mol. Microbiol. 2017, 105, 175.
[CrossRef] [PubMed]
Antibiotics 2018, 7, 41 10 of 13
43. Park, S.S.; Yang, Y.H.; Song, E.; Kim, E.J.; Kim, W.S.; Sohng, J.K.; Lee, H.C.; Liou, K.K.; Kim, B.G.
Mass spectrometric screening of transcriptional regulators involved in antibiotic biosynthesis in Streptomyces
coelicolor A3(2). J. Ind. Microbiol. Biotechnol. 2009, 36, 1073–1083. [CrossRef] [PubMed]
44. Liu, G.; Chater, K.F.; Chandra, G.; Niu, G.; Tan, H. Molecular regulation of antibiotic biosynthesis in
streptomyces. Microbiol. Mol. Biol. Rev. 2013, 77, 112–143. [CrossRef] [PubMed]
45. Pimentel-Elardo, S.M.; Sorensen, D.; Ho, L.; Ziko, M.; Bueler, S.A.; Lu, S.; Tao, J.; Moser, A.; Lee, R.;
Agard, D.; et al. Activity-independent discovery of secondary metabolites using chemical elicitation and
cheminformatic inference. ACS Chem. Biol. 2015, 10, 2616–2623. [CrossRef] [PubMed]
46. Van Dissel, D.; Claessen, D.; Roth, M.; van Wezel, G.P. A novel locus for mycelial aggregation forms a
gateway to improved streptomyces cell factories. Microb. Cell Fact. 2015, 14, 44. [CrossRef] [PubMed]
47. Chaplin, A.K.; Petrus, M.L.; Mangiameli, G.; Hough, M.A.; Svistunenko, D.A.; Nicholls, P.; Claessen, D.;
Vijgenboom, E.; Worrall, J.A. Glxa is a new structural member of the radical copper oxidase family and is
required for glycan deposition at hyphal tips and morphogenesis of Streptomyces lividans. Biochem. J. 2015,
469, 433–444. [CrossRef] [PubMed]
48. Petrus, M.L.; Vijgenboom, E.; Chaplin, A.K.; Worrall, J.A.; van Wezel, G.P.; Claessen, D. The dyp-type
peroxidase dtpa is a tat-substrate required for glxa maturation and morphogenesis in streptomyces. Open Biol.
2016, 6, 150149. [CrossRef] [PubMed]
49. Petrus, M.L.; Claessen, D. Pivotal roles for streptomyces cell surface polymers in morphological
differentiation, attachment and mycelial architecture. Antonie Van Leeuwenhoek 2014, 106, 127–139. [CrossRef]
[PubMed]
50. Susstrunk, U.; Pidoux, J.; Taubert, S.; Ullmann, A.; Thompson, C.J. Pleiotropic effects of camp on germination,
antibiotic biosynthesis and morphological development in Streptomyces coelicolor. Mol. Microbiol. 1998, 30,
33–46. [CrossRef] [PubMed]
51. De Jong, W.; Manteca, A.; Sanchez, J.; Bucca, G.; Smith, C.P.; Dijkhuizen, L.; Claessen, D.; Wosten, H.A.
Nepa is a structural cell wall protein involved in maintenance of spore dormancy in Streptomyces coelicolor.
Mol. Microbiol. 2009, 71, 1591–1603. [CrossRef] [PubMed]
52. Bobek, J.; Strakova, E.; Zikova, A.; Vohradsky, J. Changes in activity of metabolic and regulatory pathways
during germination of S. coelicolor. BMC Genomics 2014, 15, 1173. [CrossRef] [PubMed]
53. Rioseras, B.; Yague, P.; Lopez-Garcia, M.T.; Gonzalez-Quinonez, N.; Binda, E.; Marinelli, F.; Manteca, A.
Characterization of SCO4439, a D-alanyl-D-alanine carboxypeptidase involved in spore cell wall maturation,
resistance, and germination in Streptomyces coelicolor. Sci. Rep. 2016, 6, 21659. [CrossRef] [PubMed]
54. Sexton, D.L.; St-Onge, R.J.; Haiser, H.J.; Yousef, M.R.; Brady, L.; Gao, C.; Leonard, J.; Elliot, M.A.
Resuscitation-promoting factors are Cell wall-lytic enzymes with important roles in the germination and
growth of Streptomyces coelicolor. J. Bacteriol. 2015, 197, 848–860. [CrossRef] [PubMed]
55. Noens, E.E.; Mersinias, V.; Willemse, J.; Traag, B.A.; Laing, E.; Chater, K.F.; Smith, C.P.; Koerten, H.K.;
van Wezel, G.P. Loss of the controlled localization of growth stage-specific cell-wall synthesis pleiotropically
affects developmental gene expression in an ssga mutant of Streptomyces coelicolor. Mol. Microbiol. 2007, 64,
1244–1259. [CrossRef] [PubMed]
56. Zacchetti, B.; Willemse, J.; Recter, B.; van Dissel, D.; van Wezel, G.P.; Wosten, H.A.; Claessen, D. Aggregation
of germlings is a major contributing factor towards mycelial heterogeneity of streptomyces. Sci. Rep. 2016,
6, 27045. [CrossRef] [PubMed]
57. Girard, G.; Traag, B.A.; Sangal, V.; Mascini, N.; Hoskisson, P.A.; Goodfellow, M.; van Wezel, G.P. A novel
taxonomic marker that discriminates between morphologically complex actinomycetes. Open Biol. 2013,
3, 130073. [CrossRef] [PubMed]
58. Ronnest, N.P.; Stocks, S.M.; Lantz, A.E.; Gernaey, K.V. Comparison of laser diffraction and image analysis
for measurement of Streptomyces coelicolor cell clumps and pellets. Biotechnol. Lett. 2012, 34, 1465–1473.
[CrossRef] [PubMed]
59. Van Veluw, G.J.; Petrus, M.L.; Gubbens, J.; de Graaf, R.; de Jong, I.P.; van Wezel, G.P.; Wosten, H.A.;
Claessen, D. Analysis of two distinct mycelial populations in liquid-grown streptomyces cultures using a
flow cytometry-based proteomics approach. Appl. Microbiol. Biotechnol. 2012, 96, 1301–1312. [CrossRef]
[PubMed]
60. Petrus, M.L.; van Veluw, G.J.; Wosten, H.A.; Claessen, D. Sorting of streptomyces cell pellets using a complex
object parametric analyzer and sorter. J. Vis. Exp. 2014, e51178. [CrossRef] [PubMed]
Antibiotics 2018, 7, 41 11 of 13
61. Willemse, J.; Buke, F.; van Dissel, D.; Grevink, S.; Claessen, D.; van Wezel, G.P. Sparticle, an algorithm for
the analysis of filamentous microorganisms in submerged cultures. Antonie Van Leeuwenhoek 2017, 171–182.
[CrossRef]
62. Celler, K.; Cristian, P.; van Loosdrecht, M.C.; van Wezel, G.P. Structured morphological modeling as a
framework for rational strain design of streptomyces species. Antonie Van Leeuwenhoek 2012, 102, 409–423.
[CrossRef] [PubMed]
63. Nieminen, L.; Webb, S.; Smith, M.C.; Hoskisson, P.A. A flexible mathematical model platform for studying
branching networks: Experimentally validated using the model actinomycete, Streptomyces coelicolor.
PLoS ONE 2013, 8, e54316. [CrossRef] [PubMed]
64. Van Dissel, D.; Claessen, D.; van Wezel, G.P. Morphogenesis of streptomyces in submerged cultures.
Adv. Appl. Microbiol. 2014, 89, 1–45. [PubMed]
65. Ha, S.; Lee, K.J.; Lee, S.I.; Gwak, H.J.; Lee, J.H.; Kim, T.W.; Choi, H.J.; Jang, J.Y.; Choi, J.S.; Kim, C.J.;
et al. Optimization of herbicidin a production in submerged culture of streptomyces scopuliridis m40.
J. Microbiol. Biotechnol. 2017, 27, 947–955. [CrossRef] [PubMed]
66. Van Dissel, D.; van Wezel, G.P. Morphology-driven downscaling of streptomyces lividans to
micro-cultivation. Antonie Van Leeuwenhoek 2017, 457–469. [CrossRef]
67. Rigali, S.; Nothaft, H.; Noens, E.E.; Schlicht, M.; Colson, S.; Müller, M.; Joris, B.; Koerten, H.K.;
Hopwood, D.A.; Titgemeyer, F.; van Wezel, G.P. The sugar phosphotransferase system of Streptomyces
coelicolor is regulated by the gntr-family regulator dasr and links n-acetylglucosamine metabolism to the
control of development. Mol. Microbiol. 2006, 61, 1237–1251. [CrossRef] [PubMed]
68. Rigali, S.; Titgemeyer, F.; Barends, S.; Mulder, S.; Thomae, A.W.; Hopwood, D.A.; van Wezel, G.P. Feast or
famine: The global regulator dasr links nutrient stress to antibiotic production by streptomyces. EMBO Rep.
2008, 9, 670–675. [CrossRef] [PubMed]
69. Yague, P.; Manteca, A.; Simon, A.; Diaz-Garcia, M.E.; Sanchez, J. New method for monitoring programmed
cell death and differentiation in submerged streptomyces cultures. Appl. Environ. Microbiol. 2010, 76,
3401–3404. [CrossRef] [PubMed]
70. Yague, P.; Lopez-Garcia, M.T.; Rioseras, B.; Sanchez, J.; Manteca, A. Pre-sporulation stages of streptomyces
differentiation: State-of-the-art and future perspectives. FEMS Microbiol. Lett. 2013, 342, 79–88. [CrossRef]
[PubMed]
71. Innes, C.M.; Allan, E.J. Induction, growth and antibiotic production of streptomyces viridifaciens l-form
bacteria. J. Appl. Microbiol. 2001, 90, 301–308. [CrossRef] [PubMed]
72. Kealey, C.; Creaven, C.A.; Murphy, C.D.; Brady, C.B. New approaches to antibiotic discovery. Biotechnol. Lett.
2017, 39, 805–817. [CrossRef] [PubMed]
73. Bai, L.; Liu, C.; Guo, L.; Piao, C.; Li, Z.; Li, J.; Jia, F.; Wang, X.; Xiang, W. Streptomyces formicae sp. Nov.,
a novel actinomycete isolated from the head of Camponotus japonicus mayr. Antonie Van Leeuwenhoek 2016,
109, 253–261. [CrossRef] [PubMed]
74. Sarmiento-Vizcaino, A.; Brana, A.F.; Gonzalez, V.; Nava, H.; Molina, A.; Llera, E.; Fiedler, H.P.; Rico, J.M.;
Garcia-Florez, L.; Acuna, J.L.; et al. Atmospheric dispersal of bioactive Streptomyces albidoflavus strains
among terrestrial and marine environments. Microb. Ecol. 2016, 71, 375–386. [CrossRef] [PubMed]
75. Sarmiento-Vizcaino, A.; Gonzalez, V.; Brana, A.F.; Palacios, J.J.; Otero, L.; Fernandez, J.; Molina, A.; Kulik, A.;
Vazquez, F.; Acuna, J.L.; et al. Pharmacological potential of phylogenetically diverse actinobacteria isolated
from deep-sea coral ecosystems of the submarine aviles canyon in the cantabrian sea. Microb. Ecol. 2017, 73,
338–352. [CrossRef] [PubMed]
76. Schniete, J.K.; Cruz-Morales, P.; Selem-Mojica, N.; Fernandez-Martinez, L.T.; Hunter, I.S.; Barona-Gomez, F.;
Hoskisson, P.A. Expanding primary metabolism helps generate the metabolic robustness to facilitate
antibiotic biosynthesis in streptomyces. MBio 2018, 9. [CrossRef] [PubMed]
77. Cihak, M.; Kamenik, Z.; Smidova, K.; Bergman, N.; Benada, O.; Kofronova, O.; Petrickova, K.; Bobek, J.
Secondary metabolites produced during the germination of Streptomyces coelicolor. Front. Microbiol. 2017,
8, 2495. [CrossRef] [PubMed]
78. Yu, G.; Jia, X.; Wen, J.; Lu, W.; Wang, G.; Caiyin, Q.; Chen, Y. Strain improvement of streptomyces roseosporus
for daptomycin production by rational screening of he-ne laser and NTG induced mutants and kinetic
modeling. Appl. Biochem. Biotechnol. 2011, 163, 729–743. [CrossRef] [PubMed]
Antibiotics 2018, 7, 41 12 of 13
79. Jakeman, D.L.; Graham, C.L.; Young, W.; Vining, L.C. Culture conditions improving the production of
jadomycin b. J. Ind. Microbiol. Biotechnol. 2006, 33, 767–772. [CrossRef] [PubMed]
80. Bode, H.B.; Bethe, B.; Hofs, R.; Zeeck, A. Big effects from small changes: Possible ways to explore nature’s
chemical diversity. Chembiochem 2002, 3, 619–627. [CrossRef]
81. Bursy, J.; Kuhlmann, A.U.; Pittelkow, M.; Hartmann, H.; Jebbar, M.; Pierik, A.J.; Bremer, E. Synthesis and
uptake of the compatible solutes ectoine and 5-hydroxyectoine by Streptomyces coelicolor A3(2) in response to
salt and heat stresses. Appl. Environ. Microbiol. 2008, 74, 7286–7296. [CrossRef] [PubMed]
82. Hayes, A.; Hobbs, G.; Smith, C.P.; Oliver, S.G.; Butler, P.R. Environmental signals triggering methylenomycin
production by Streptomyces coelicolor A3(2). J. Bacteriol. 1997, 179, 5511–5515. [CrossRef] [PubMed]
83. Medema, M.H.; Alam, M.; Breitling, R.; Takano, E. The future of industrial antibiotic production:
From random mutagenesis to synthetic biology. Bioeng. Bugs. 2011, 230–233. [CrossRef]
84. Cheng, Y.R.; Huang, J.; Qiang, H.; Lin, W.L.; Demain, A.L. Mutagenesis of the rapamycin producer
streptomyces hygroscopicus FC904. J. Antibiot. 2001, 54, 967–972. [CrossRef] [PubMed]
85. Wang, G.; Hosaka, T.; Ochi, K. Dramatic activation of antibiotic production in Streptomyces coelicolor by
cumulative drug resistance mutations. Appl. Environ. Microbiol. 2008, 74, 2834–2840. [CrossRef] [PubMed]
86. McKenzie, N.L.; Thaker, M.; Koteva, K.; Hughes, D.W.; Wright, G.D.; Nodwell, J.R. Induction of antimicrobial
activities in heterologous streptomycetes using alleles of the Streptomyces coelicolor gene absa1. J. Antibiot.
2010, 63, 177–182. [CrossRef] [PubMed]
87. Foley, T.L.; Young, B.S.; Burkart, M.D. Phosphopantetheinyl transferase inhibition and secondary metabolism.
FEBS J. 2009, 276, 7134–7145. [CrossRef] [PubMed]
88. Onaka, H. Biosynthesis of indolocarbazole and goadsporin, two different heterocyclic antibiotics produced
by actinomycetes. Biosci. Biotechnol. Biochem. 2009, 73, 2149–2155. [CrossRef] [PubMed]
89. Recio, E.; Colinas, A.; Rumbero, A.; Aparicio, J.F.; Martin, J.F. Pi factor, a novel type quorum-sensing inducer
elicits pimaricin production in streptomyces natalensis. J. Biol. Chem. 2004, 279, 41586–41593. [CrossRef]
[PubMed]
90. Mo, S.; Ban, Y.H.; Park, J.W.; Yoo, Y.J.; Yoon, Y.J. Enhanced FK506 production in Streptomyces clavuligerus
ckd1119 by engineering the supply of methylmalonyl-coa precursor. J. Ind. Microbiol. Biotechnol. 2009, 36,
1473–1482. [CrossRef] [PubMed]
91. Liu, Z.; Guo, M.; Qian, J.; Zhuang, Y.; Zhang, S. Disruption of ZWF2 gene to improve oxytetraclyline
biosynthesis in streptomyces rimosus M4018. Wei Sheng Wu Xue Bao 2008, 48, 21–25. [PubMed]
92. Yagüe, P.; Manteca, A. Optimization of the antibiotic producction in different Streptomyces strains by
conditioning the MII differentiation. 2018. Unpublished results.
93. Malla, S.; Niraula, N.P.; Liou, K.; Sohng, J.K. Self-resistance mechanism in streptomyces peucetius:
Overexpression of drra, drrb and drrc for doxorubicin enhancement. Microbiol. Res. 2010, 165, 259–267.
[CrossRef] [PubMed]
94. Qiu, J.; Zhuo, Y.; Zhu, D.; Zhou, X.; Zhang, L.; Bai, L.; Deng, Z. Overexpression of the abc transporter avtab
increases avermectin production in streptomyces avermitilis. Appl. Microbiol. Biotechnol. 2011, 92, 337–345.
[CrossRef] [PubMed]
95. Xu, Y.; Willems, A.; Au-Yeung, C.; Tahlan, K.; Nodwell, J.R. A two-step mechanism for the activation of
actinorhodin export and resistance in Streptomyces coelicolor. MBio 2012, 3, e00191-12. [CrossRef] [PubMed]
96. McKenzie, N.L.; Nodwell, J.R. Phosphorylated absa2 negatively regulates antibiotic production in
Streptomyces coelicolor through interactions with pathway-specific regulatory gene promoters. J. Bacteriol.
2007, 189, 5284–5292. [CrossRef] [PubMed]
97. Guo, J.; Zhao, J.; Li, L.; Chen, Z.; Wen, Y. Li, J. The pathway-specific regulator aver from Streptomyces
avermitilis positively regulates avermectin production while it negatively affects oligomycin biosynthesis.
Mol. Genet. Genomics 2010, 283, 123–133. [CrossRef] [PubMed]
98. Retzlaff, L.; Distler, J. The regulator of streptomycin gene expression, strr, of streptomyces griseus is a DNA
binding activator protein with multiple recognition sites. Mol. Microbiol. 1995, 18, 151–162. [CrossRef]
[PubMed]
99. Laureti, L.; Song, L.; Huang, S.; Corre, C.; Leblond, P.; Challis, G.L.; Aigle, B. Identification of a bioactive
51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens.
Proc. Natl. Acad. Sci. USA 2011, 108, 6258–6626. [CrossRef] [PubMed]
Antibiotics 2018, 7, 41 13 of 13
100. Menendez, N.; Brana, A.F.; Salas, J.A.; Mendez, C. Involvement of a chromomycin abc transporter system in
secretion of a deacetylated precursor during chromomycin biosynthesis. Microbiology 2007, 153, 3061–3070.
[CrossRef] [PubMed]
101. Bunet, R.; Song, L.; Mendes, M.V.; Corre, C.; Hotel, L.; Rouhier, N.; Framboisier, X.; Leblond, P.; Challis, G.L.;
Aigle, B. Characterization and manipulation of the pathway-specific late regulator alpw reveals Streptomyces
ambofaciens as a new producer of kinamycins. J. Bacteriol. 2010. [CrossRef] [PubMed]
102. Gomez-Escribano, J.P.; Bibb, M.J. Engineering Streptomyces coelicolor for heterologous expression of secondary
metabolite gene clusters. Microb. Biotechnol. 2011, 4, 207–215. [CrossRef] [PubMed]
103. Komatsu, M.; Uchiyama, T.; Omura, S.; Cane, D.E.; Ikeda, H. Genome-minimized streptomyces host for
the heterologous expression of secondary metabolism. Proc. Natl. Acad. Sci. USA 2010, 107, 2646–2651.
[CrossRef] [PubMed]
104. Novakova, R.; Nunez, L.E.; Homerova, D.; Knirschova, R.; Feckova, L.; Rezuchova, B.; Sevcikova, B.;
Menendez, N.; Moris, F.; Cortes, J.; et al. Increased heterologous production of the antitumoral polyketide
mithramycin a by engineered streptomyces lividans TK24 strains. Appl. Microbiol. Biotechnol. 2018, 102,
857–869. [CrossRef] [PubMed]
105. Kawahara, T.; Izumikawa, M.; Kozone, I.; Hashimoto, J.; Kagaya, N.; Koiwai, H.; Komatsu, M.; Fujie, M.;
Sato, N.; Ikeda, H.; et al. Neothioviridamide, a polythioamide compound produced by heterologous
expression of a Streptomyces sp. Cryptic ripp biosynthetic gene cluster. J. Nat. Prod. 2018, 264–269. [CrossRef]
[PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
